Category Archives: MRK
Notes and Analysis from Merck’s Investor Day
On June 20, Merck held an investor day, its first in five years, to highlight its goals and objectives and provide a broad perspective on its five-year performance outlook. Although its blockbuster cancer treatment, KEYTRUDA (pembrolizumab), has been a spectacular … Continue reading
Posted in Health Care, MRK
Tagged Merck, Pharmaceutical industry
Comments Off on Notes and Analysis from Merck’s Investor Day
An Update on Merck (MRK)
Product Pipeline Successes. Merck has enjoyed a couple of notable successes in its product pipeline over the past year. The first and most important is Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) immunotherapy treatment for cancer. Keytruda has already … Continue reading
Posted in Financial Reporting, MRK
Tagged Accounting, GAAP vs. Non-GAAP
Comments Off on An Update on Merck (MRK)